surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Company profile
Ticker
SURF
Exchange
Website
CEO
J. Jeffrey Goater
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
SURF stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
15 Sep 23
EFFECT
Notice of effectiveness
13 Sep 23
EFFECT
Notice of effectiveness
13 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Sep 23
POS AM
Prospectus update (post-effective amendment)
8 Sep 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
54.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 66 |
Opened positions | 13 |
Closed positions | 21 |
Increased positions | 7 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 15.68 bn |
Total shares | 32.83 mm |
Total puts | 20.00 k |
Total calls | 51.20 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 4.89 mm | $4.25 bn |
Novartis Institutes for BioMedical Research | 3.95 mm | $36.48 mm |
Lilly Ventures Fund I | 3.45 mm | $31.86 mm |
Atlas Venture Associates IX | 2.95 mm | $2.56 bn |
Atlas Venture Fund IX | 2.95 mm | $0.00 |
Vanguard | 2.31 mm | $2.01 bn |
LLY Lilly(Eli) & Co | 1.59 mm | $7.62 mm |
Venrock Healthcare Capital Partners II | 1.44 mm | $13.33 mm |
ARK Investment Management | 1.41 mm | $1.23 bn |
DAFNA Capital Management | 1.10 mm | $956.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Sep 23 | Henry C. Rath | Common Stock | Sale back to company | Dispose D | No | No | 0 | 44,971 | 0.00 | 0 |
8 Sep 23 | Henry C. Rath | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.69 | 150,000 | 103.50 k | 0 |
8 Sep 23 | Goater Jeff | Common Stock | Sale back to company | Dispose D | No | No | 0 | 129,222 | 0.00 | 0 |
8 Sep 23 | Robert W. Ross | Common Stock | Sale back to company | Dispose D | No | No | 0 | 83,193 | 0.00 | 0 |
8 Sep 23 | Robert W. Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.69 | 400,000 | 276.00 k | 0 |
8 Sep 23 | Sigal Charles Elliott | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 45,453 | 0.00 | 0 |
8 Sep 23 | Sigal Charles Elliott | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.35 | 113,636 | 39.77 k | 0 |
8 Sep 23 | Chandra Adams | Common Stock | Sale back to company | Dispose D | No | No | 0 | 23,884 | 0.00 | 0 |
8 Sep 23 | Chandra Adams | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.69 | 50,000 | 34.50 k | 0 |
8 Sep 23 | Chandra Adams | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.69 | 50,000 | 34.50 k | 0 |